Widely-Used Citicoline Found to Be Ineffective in TBI Treatment

by U.S. Medicine

December 13, 2012

By Brenda L. Mooney

BOSTON – A compound approved for treating traumatic brain injury (TBI) in nearly 60 countries does not appear to approve function or cognitive status in patients, according to a new study.

The report was on a randomized trial of more than 1,200 participants with TBI that looked at the effectiveness of citicoline, an endogenous compound available as a dietary supplement in the United States but sold as a prescription medication in some other countries.1

“The COBRIT study indicates that citicoline was not superior to placebo as an acute and post-acute therapy among participants with a broad range of severity of TBI. The worldwide use of citicoline for TBI should now be questioned,” writes lead author Ross D. Zafonte, DO, of Harvard Medical School, Spaulding Rehabilitation and Massachusetts General Hospital, Boston, and colleagues. Their report was published last month in the Journal of the American Medical Association.

Citicoline was developed in Japan to treat stroke but now is frequently prescribed in Europe for cognitive issues related to circulation problems in the brain. In addition to TBI, it is used for Alzheimer’s disease and other types of dementia, cerebrovascular disease such as stroke, age-related memory loss, Parkinson’s disease, attention deficit-hyperactive disorder (ADHD) and glaucoma.

Its mechanism of action appears to be increasing a brain chemical called phosphatidylcholine, and some proponents have suggested citicoline also can decrease brain tissue damage after injury.

“Despite considerable advances in emergency and critical care management of TBI, as well as decades of research on potential agents for neuroprotection or enhanced recovery, no effective pharmacotherapy has yet been identified,” according to background information contained in the article.

The study reported in JAMA, the Citicoline Brain Injury Treatment Trial (COBRIT), was a phase 3, randomized clinical trial conducted between July 2007 and February 2011. Researchers examined the effects of 90 days of enteral or oral citicoline (2,000 mg) vs. placebo initiated within 24 hours of injury in 1,213 patients with complicated mild, moderate and severe TBI at eight U.S. level 1 trauma centers.

Citicoline and placebo groups did not differ significantly at the 90-day evaluation on measures of cognitive and functional status, according to the results.

“Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicoline group and 35.6%,” the authors note. With other measurement tools,” the rate of improvement ranged from 37.3% to 86.5% in the citicoline group and from 42.7% to 84.0% in the placebo group.”

Treatment effect with citicoline didn’t differ between the moderate/severe and complicated mild TBI subgroups. Nor was much difference observed between placebo and citicoline in the overall proportion of patients reporting serious adverse events.

Although prior meta-analyses suggest that neuropsychological function might return to normal by three months in the majority of patients with uncomplicated mild TBI, this is untrue for those with so-called mild injury complicated by cerebral injuries visible on CT,” the authors suggest.

“The TBI Clinical Trials Network Core Battery includes sensitive measures of cognition, chosen because ceiling effects were unlikely. Thus, the COBRIT study appears to support the lack of utility of citicoline in the treatment of TBI across a broad spectrum of injury severity,” the report said.

In an accompanying editorial, Robert L. Ruff, MD, PhD, and Ronald G. Riechers II, MD, both of the Louis Stokes Cleveland VA Medical Center and Case Western Reserve University, said the primary importance of the trial “is that it conclusively demonstrated the lack of efficacy of citicoline monotherapy for TBI.”2

Ruff and Riechers add, “it is unlikely that this finding can be accounted for by limitations in the study design or conduct. The broader implication of the COBRIT study may be that no single therapeutic agent is likely to be sufficient to improve functional outcomes for patients with TBI. The diverse and complex nature of the pathological mechanisms activated by TBI suggests that multimodal treatment interventions may be needed to improve recovery.”

They suggest that future studies of TBI treatment focus on multiple treatment interventions and comprehensive TBI rehabilitation strategies.

The editorial writers point out that “reducing the severity of TBI morbidity once trauma has occurred and improving the rate and extent of recovery from TBI are major challenges,” saying that the results of the COBRIT study had been anticipated with “great hope.”

1. Zafonte RD; DO, Bagiella E; Ansel BM; Novack TA, et al. Effect of Citicoline on Functional and Cognitive Status Among Patients With Traumatic Brain Injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308(19):1993-2000. doi:10.1001/jama.2012.13256

2. Ruff RL, Richers RG. Effective Treatment of Traumatic Brain Injury: Learning From Experience. JAMA. 2012;308(19):2032-2033. doi:10.1001/jama.2012.14008


Comments are closed here.


Related Articles

Ensuring Community Providers Meet Veteran Suicide Prevention Standards

WASHINGTON—As leaders from across multiple federal agencies begin work on a roadmap to combat veteran suicide, they are searching for ways to turn existing efforts in towns, cities, counties and neighborhoods across the country into... View Article

VA Manages Drug Costs Better than Medicare Part D

ST. LOUIS – Medicare Part D could save more than $14 billion annually if it paid the same prices for top medications as the VA, according to a new study. A research letter published earlier... View Article


U.S. Medicine Recommends


More From department of veterans affairs

Department of Veterans Affairs (VA)

Ensuring Community Providers Meet Veteran Suicide Prevention Standards

WASHINGTON—As leaders from across multiple federal agencies begin work on a roadmap to combat veteran suicide, they are searching for ways to turn existing efforts in towns, cities, counties and neighborhoods across the country into... View Article

Department of Veterans Affairs (VA)

VA Manages Drug Costs Better than Medicare Part D

ST. LOUIS – Medicare Part D could save more than $14 billion annually if it paid the same prices for top medications as the VA, according to a new study. A research letter published earlier... View Article

Department of Veterans Affairs (VA)

House Passes Bill to Create Education/Employment Arm of VA

WASHINGTON,—Legislators have reintroduced plans to create a fourth administration within the Department of Veterans Affairs—one dedicated to overseeing veterans’ education, transition and employment benefits. Currently these operations fall under the Veterans Benefits Administration, with VBA... View Article

Department of Veterans Affairs (VA)

Administrative Confusions Results in Little Oversight of VA’s Police Force

Suicides, Violence at VMACs Put Spotlight on Security WASHINGTON—As the number of suicides and other violent incidents at VA facilities grows, a spotlight is being thrown on VA’s internal police force and its ability to... View Article

Department of Veterans Affairs (VA)

Veterans Using Dual Health Systems Have More Problems With Medications

CHARLESTON, SC—More than half of the patients treated by VA are also Medicare eligible, and that is increasing the risk for a range of prescription medication problems—from chronic disease medication nonadherence to opioid overdoses—among dual... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up